-
-
-
-
-
-
-
Morgan Stanley on Ultragenyx Pharma (RARE): BLA submission acceptance removes key overhang
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE)
-
-
-
-
-
-
-
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndro
-
-
-
-
-
-
-
Ultragenyx Reports First Quarter 2020 Financial Results and Corporate Update
-
-
-
-
-
-
-
Ultragenyx Reports Preliminary 2019 Revenue and Provides 2020 Crysvita Revenue Guidance
-
-
-
-
-
-
-
Kyowa Kirin, Ultragenyx (RARE) Announce Crysvita Receives Conditional Marketing Authorisation in Europe for Treatment of X-Linked Hypophosphatemia in Children
-
15,923 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


